Vivus settles patent litigation case with Dr Reddy's

In 2015, Vivid filed a patent infringement case against Dr Reddy's

premium

Novartis is addressing the pricing question with a new type of agreement: For patients whose care is covered by the US govt programmes, the company will only get paid if patients show signs that the treatment is working within a month | Photo: istock

BS Reporter Hyderabad

Last Updated : Sep 01 2017 | 2:49 PM IST

American pharmaceutical company Vivus, Inc has entered into a settlement agreement with Dr Reddy's Laboratories Limited's US subsidiaries in a patent litigation involving it's weight management drug Qsymia.

In 2015, Vivid filed a patent infringement case against Dr Reddy's after the latter filed an application to the US Food and Drug Administration (USFDA) for approval to launch a generic version of this drug.

The settlement agreement permits Dr Reddy's to begin selling a generic version of Qsymia on June 1, 2025, or earlier under certain circumstances. In the event of a launch earlier than June 1, 2025, Vivus will receive